Skip to main content
OpenTrials
Completed

NCT Number: NCT01510717

Clinical Investigation of AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2 [SV25T0]

The purpose of this study is to compare the safety and efficacy of an investigational multifocal intraocular lens (IOL) to an FDA-approved monofocal IOL.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cataracts Cataract Eye Diseases Lens Diseases

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Participants 21 years and older in need of cataract extraction were consented and randomized in a 1:1 ratio at each investigative site to receive either the AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0] or the AcrySof® IQ Monofocal IOL Model SN60WF in both eyes. Each participant completed a preoperative examination of both eyes, implantation of IOL at the operative visit for each eye, and up to 7 postoperative visits, with monocular testing at Day 1-2, Day 7-14, and Day 30-60, and monocular and binocular testing at Day 120-180 following the second implantation. The first eye to be implanted was considered the primary eye. The second eye was implanted 7 and 30 days of the first. If the first eye was not implanted during surgery, the second eye was not eligible. If the second eye was not implanted during surgery, only the first eye was followed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of bilateral cataracts
  • Willing and able to complete all required postoperative visits
  • Calculated lens power within the available supply range
  • Planned cataract removal by phacoemulsification
  • Potential postoperative visual acuity of 0.2 logMAR or better in both eyes
  • Preoperative astigmatism less than 1.0 diopter
  • Clear intraocular media other than cataract in study eyes
  • Preoperative Best Corrected Distance Visual Acuity (BCDVA) worse than 0.2 logMAR
  • Able to undergo second eye surgery between 7 days and 30 days of the first eye surgery
  • Other protocol-defined inclusion criteria may apply

Exclusion criteria

  • Previous refractive surgery
  • Inflammation or edema of the cornea
  • Optic nerve atrophy
  • Pregnancy
  • Current participation in another investigational drug or device study
  • Other protocol-defined exclusion criteria may apply

Treatment and study plan

AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]

Device

Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient

ACRYSOF® IQ Monofocal IOL Model SN60WF

Device

Monofocal IOL implanted for long-term use over the lifetime of the cataract patient

Primary outcomes

  1. Mean Photopic Monocular Distance Corrected VA (53 cm) at Day 120-180

    Time frame: Day 120-180 from second eye implantation

    Visual acuity (VA) was tested monocularly (each eye separately) using the manifest refraction adjusted for optical infinity and the hand-held, 100% contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 53 centimeters (cm) on the nearpoint rod. VA was measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.

  2. Number of Cumulative and Persistent Adverse Events as Defined in IS EN ISO 11979-7:2006, up to Day 120-180

    Time frame: Day 0 first operative eye visit, up to Day 120-180 from second eye implantation

    Cumulative and persistent adverse events were collected. This outcome measure was prespecified for the multifocal IOL.

  3. Photopic Contrast Sensitivity Without Glare at Day 120-180

    Time frame: Day 120-180 from second eye implantation

    Contrast sensitivity (ie, the ability to detect objects by distinguishing them from their background) was assessed binocularly with the participant's best spectacle correction under photopic (bright) conditions at a distance of 8 feet at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd) using the Vector Vision CSV 1000 without a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.

  4. Photopic Contrast Sensitivity With Glare at Day 120-180

    Time frame: Day 120-180 from second eye implantation

    Contrast sensitivity was assessed binocularly with the participant's best spectacle correction under photopic (bright) conditions at a distance of 8 feet at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd) using the Vector Vision CSV 1000 with a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.

  5. Mesopic Contrast Sensitivity Without Glare at Day 120-180

    Time frame: Day 120-180 from second eye implantation

    Contrast sensitivity was assessed binocularly with the participant's best spectacle correction under mesopic (dim lighting) conditions at a distance of 8 feet at spatial frequencies of 1.5, 3, 6, and 12 cycles per degree (cpd) using the Vector Vision CSV 1000 without a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.

  6. Mesopic Contrast Sensitivity With Glare at Day 120-180

    Time frame: Day 120-180 from second eye implantation

    Contrast sensitivity was assessed binocularly with the participant's best spectacle correction under mesopic conditions at a distance of 8 feet at spatial frequencies of 1.5, 3, 6, and 12 cpd using the Vector Vision CSV 1000 with a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.

Secondary outcomes

  1. Mean Photopic Monocular Best Corrected Distance VA (4 m) at Day 120-180

    Time frame: Day 120-180 from second eye implantation

    VA was tested monocularly (each eye separately) using the correction obtained from the manifest refraction and 100% contrast, ETDRS charts at a distance of 4 meters. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.

  2. Mean Photopic Monocular Distance Corrected Near VA at Standard Distance (40 cm) at Day 120-180

    Time frame: Day 120-180 from second eye implantation

    VA was tested monocularly (each eye separately) using the manifest refraction adjusted for optical infinity and the hand-held, 100% contrast, ETDRS chart set at 40 cm on the nearpoint rod. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.

  3. Overall Spectacle Independence Using SILVER Patient Reported Outcome (PRO) Questionnaire at Day 120-180

    Time frame: Day 120-180 from second eye implantation

    Overall Spectacle Independence was rated using SILVER (Spectacle Independence Lens Vision Evaluation and Repurchase), a new patient reported outcome questionnaire. The participant was asked, "How often do you wear eyeglasses or contact lenses overall?"

  4. Near Spectacle Independence Using SILVER Patient Reported Outcome (PRO) Questionnaire at Day 120-180

    Time frame: Day 120-180 from second eye implantation

    Near Spectacle Independence was rated using SILVER, a new patient reported outcome questionnaire. The participant was asked, "How often do you wear eyeglasses or contact lenses for seeing objects up close?"

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Official study title

Clinical Investigation of AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Jan 16, 2012
Registry last updated
May 27, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.